Related Experiment Video
Updated: May 16, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment
Beatriz E Jimenez Munarriz1, Sam Khan1,2, Yuchen Li1,3,4
1Medical Oncology Department, University Health Network-Princess Margaret Cancer Center, Toronto, Ontario, Canada.
Abstract:
Lung cancer is the leading cause of cancer death worldwide. However, since the discovery and development of targeted therapies and immune checkpoint inhibitors, it has been a dramatically improved in survival outcomes and quality of life. Anaplastic lymphoma kinase (ALK) rearrangements occur in approximately 5% of patients with advanced non-small cell lung cancer (NSCLC), and the introduction of ALK tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm. Although head-to-head randomized controlled trials for late generation inhibitors are lacking, the authors will review the current available options, treatments efficacy, safety profiles, ALK mechanisms of resistance, as well as new promising treatments in this field.
Insights
Anaplastic lymphoma kinase (ALK) rearrangements impact advanced non-small cell lung cancer (NSCLC) treatment. ALK tyrosine kinase inhibitors (TKIs) improve outcomes, and this review covers current options, efficacy, and future directions.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Lung cancer remains a leading cause of cancer mortality globally.
- Targeted therapies and immune checkpoint inhibitors have significantly improved survival and quality of life for patients.
- Anaplastic lymphoma kinase (ALK) rearrangements are found in about 5% of advanced non-small cell lung cancer (NSCLC) cases.
Purpose of the Study:
- To review current treatment options for ALK-rearranged NSCLC.
- To discuss the efficacy, safety, and resistance mechanisms of ALK tyrosine kinase inhibitors (TKIs).
- To explore promising new treatments in the field of ALK-targeted therapy.
Main Methods:
- Literature review of available data on ALK inhibitors.
- Analysis of treatment efficacy and safety profiles.
- Examination of ALK resistance mechanisms and emerging therapies.
Main Results:
- ALK tyrosine kinase inhibitors (TKIs) have transformed the treatment landscape for ALK-rearranged NSCLC.
- While head-to-head trials for later-generation inhibitors are limited, existing data show varying efficacy and safety profiles.
- Understanding resistance mechanisms is crucial for optimizing treatment strategies.
Conclusions:
- ALK inhibitors represent a significant advancement in personalized medicine for NSCLC.
- Continued research into novel inhibitors and combination therapies is essential to overcome resistance and improve patient outcomes.
- This review provides a comprehensive overview of the current state and future prospects of ALK-targeted therapy in NSCLC.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy